Q1 2017 13F Holders as of 3/31/2017
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
85
-
Total 13F shares, excl. options
-
19.2M
-
Shares change
-
+3.37M
-
Total reported value, excl. options
-
$331M
-
Value change
-
+$57.7M
-
Number of buys
-
55
-
Number of sells
-
-22
-
Price
-
$17.27
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q1 2017
88 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q1 2017.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 85 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.2M shares
of 166M outstanding shares and own 11.6% of the company stock.
Largest 10 shareholders include FMR LLC (5.48M shares), BVF INC/IL (1.8M shares), PERCEPTIVE ADVISORS LLC (1.53M shares), BlackRock Inc. (1.01M shares), DEERFIELD MANAGEMENT CO (943K shares), VANGUARD GROUP INC (824K shares), EcoR1 Capital, LLC (795K shares), Redmile Group, LLC (682K shares), Tekla Capital Management LLC (530K shares), and Opaleye Management Inc. (340K shares).
This table shows the top 85 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.